Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A large real-world study found that 1 in 8 patients newly diagnosed with chronic lymphocytic leukemia (CLL) develops atrial fibrillation (AFib) within a year — and those who do face dramatically higher rates of stroke, bleeding, and heart failure. Among BTK inhibitors, zanubrutinib showed the lowest AFib rates and the fewest cardiovascular complications, suggesting drug choice could meaningfully shape heart health outcomes in CLL patients.
A major real-world analysis of over 233,000 CLL/SLL patients found that 13.1% developed atrial fibrillation (AFib) within one year of diagnosis — and the consequences were serious. Compared to patients without AFib, those who developed it had far higher rates of stroke (14.3% vs. 8.9%), bleeding events (27.9% vs. 19.1%), and heart failure (54.5% vs. 18.9%). They also racked up significantly more outpatient and inpatient healthcare visits, pointing to a heavy financial toll on the system.
The type of BTK inhibitor used for frontline treatment also made a notable difference. Among patients who started therapy, ibrutinib carried the highest AFib rate (16%), followed by acalabrutinib (13%) and zanubrutinib (11%). Among those who did develop AFib, zanubrutinib patients had a stroke rate of just 4.8% — compared to 12.2% for ibrutinib patients.
By the Numbers
Why it matters: For oncologists and cardiologists managing CLL, these findings underscore that AFib isn't just a side effect to monitor — it's a major driver of cardiovascular morbidity. Choosing a BTK inhibitor with a lower AFib profile could have real downstream benefits for patients' heart health and quality of life.
